The medical community and cultural opinion agree: clinical trials need diversity. It’s our job to serve affected populations, but we cannot do that if we don’t have an appropriate representation of these populations in our research. Minorities are often more at risk for the disease yet are egregiously underrepresented in clinical trials. Understanding why and how minority populations are underrepresented can lead us to define actionable steps that organizations of all sizes can take to help solve the problem.
“Perhaps the most straightforward action we can take is addressing the financial challenges prospective participants face. Informing underserved populations about compensation and travel stipends that are available can garner participation. And, investing in increasing those funds can also improve recruitment by addressing the income and resource gap.”
Scott continues to elaborate on actionable ways to improve trial diversity and the increased responsibility we as an industry have to make diversity a priority in the June issue of Pharmaceutical Outsourcing.
Key Topics
Understanding the Lack of Diversity in Clinical Trials
Manageable Steps for Improving Minority Recruitment and Participation
Challenges of Achieving Diversity in Rare Disease Trials
Other Diversity-Increasing Benefits of Patient Coordinators
The Lasting Impact of Purposeful Representation in Clinical Trials
Diversity is Our Responsibility
Click to read more in the original article featured on pharmaoutsourcing.com